Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.57 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | XDH | P47989 | 1/20 | 0.57 |
| ▸ | G6PD | P11413 | 1/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.52 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | MARK3 | P27448 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29724676 | 0.73 | LMNA (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL2008437 | 0.73 | LMNA (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL375936 | 0.73 | LRRK2 (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL1331751 | 0.73 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL11491986 | 0.73 | LMNA (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL8111 | 0.73 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL532632 | 0.73 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Mercaptopurine Anhydrous SCHEMBL8844 | 0.73 | LMNA (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| Adenine SCHEMBL3414606 | 0.73 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBLRRK2 | |
| SCHEMBL275945 | 0.73 | LMNA (0.57) | PI4KAPI4K2BPI4K2API4KBLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717779-A2 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | TriLink BioTechnologies, LLC (US) | 2026-04-01 | — | — | EP | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-7265111-B2 | Adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-04 | — | — | US | claimed |
| CN-1671728-A | Novel adenosine analogues and their use as pharmaceutical agents | AVENTIS PHARMA GMBH (DE) | 2005-09-21 | — | — | CN | claimed |
| EP-1527083-A1 | NOVEL ADENOSINE ANALOGUES AND THEIR USE AS PHARMACEUTICAL AGENTS | Aventis Pharma Deutschland GmbH (DE) | 2005-05-04 | — | — | EP | claimed |
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-07-01 | — | — | US | claimed |
| WO-2004003002-A1 | NOVEL ADENOSINE ANALOGUES AND THEIR USE AS PHARMACEUTICAL AGENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-08 | — | — | WO | claimed |
| EP-1375508-A1 | N6-substituted adenosine analogues and their use as pharmaceutical agents | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | claimed |
| CN-1117870-C | Method for producing nucleoside-5' -phosphate ester | AJINOMOTO KK (JP) | 2003-08-13 | — | — | CN | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0540686-A4 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1993-05-26 | — | — | EP | claimed |
| EP-0540686-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES. | US COMMERCE (US) | 1993-05-12 | — | — | EP | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
| JP-3076594-A | — | — | None | — | — | JP | disclosed |
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | TRILINK BIOTECHNOLOGIES, LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4276189-B1 | INITIATING CAPPED OLIGONUCLEOTIDE PRIMERS FOR SYNTHESIZING 5'-CAPPED RNAS | TRILINK BIOTECHNOLOGIES LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| WO-1991012260-A1 | 6-HALO- AND 2-AMINO-6-HALO-PURINE 2',3'-DIDEOXY NUCLEOSIDES AND THEIR USE AS ANTIVIRAL AGENTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-08-22 | — | — | WO | disclosed |
| JP-H0376594-A | PRODUCTION OF DIDEOXYNUCLEOTIDE DERIVATIVE | AJINOMOTO CO INC | 1991-04-02 | — | — | JP | disclosed |
| JP-H00376594-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | RNGTT, RNMT, UPF1 | PI4KA 4241/4885PI4K2B 3370/4885PI4K2A 3707/4885 |
| US-20040127434-A1 | Novel adenosine analogues and their use as pharmaceutical agents | ADORA1, ADORA2A, ADORA2B | PI4KA 845/4885PI4K2B 504/4885PI4K2A 480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.